Bioconjugates pose complex development and manufacturing challenges. This brochure describes Lonza's manufacturing capabilities and the advantages of its simplified supply chain in which intermediates and the drug substance are manufactured under one quality system, reducing risk and accelerating the timeline to clinical trials and market. To learn more, please see our brochure.
Download
Latest content

Latest briefing from the Knowledge Center

Fc-Fusion Protein
Article
De-Risk Biologics’ Expression and Manufacturing Through Early In Silico and In Vitro Assessments
Drug development has become increasingly competitive and leaves little room for error or delay....
Houston, TX facility,Woman working in lab,PD scientist in lab,CGT Houston Process Development
Poster
Novel engineered plasmids and optimized HEK293 cell line improves AAV productivity
Gene therapy developers are under increasing pressure to advance their AAV-based therapeutics for...
micro image
Article
Ramp up your AAV productivity with novel engineered plasmids and optimized HEK293 cell lines
Lonza has established experience and capabilities in rAAV production and is continually identifying...
Monoclonal Antibody Molecule
Whitepaper/Executive Summary
Lonza Shapes Biotherapeutics Development Programs Around Different CMC Paths
As protein engineering and manufacturing technologies evolve, small biotech and major pharma...
Shaped Around You Bispecific Antibody Molecule and hand
Whitepaper/Executive Summary
Flexibility Is A Critical Aspect Of Biotech-CDMO Relationships
The Lonza small biotech series highlights the critical components that smaller innovators need to...
Monoclonal Antibody Molecule Hand
Whitepaper/Executive Summary
Accessibility Is A Key Difference In Biotech-CDMO Relationships
The Lonza small biotech series highlights the critical components that innovative Biotechs need to...
Whitepaper/Executive Summary
Communication Is A Foundation For Effective Biotech-CDMO Relationships
The Lonza small biotech series highlights the critical components that smaller innovators need to...
Presentation (on-demand)
Process development for CGT: How soon is too soon? (Geleen)
During the inaugural event of expanded Process and Analytical Development Laboratories at Lonza...
SFS Lab Bend
R&D Blog post
Why is an integrated service offering so important for the modern pharmaceutical industry?
I am often asked why I believe an integrated service offering is so important for the pharmaceutical...
SM drug product
Webinar (on-demand)
CMC and CDMO: The Importance of Choosing the Right Partner
Small pharma companies are driving pipeline innovation and are increasingly taking more complex...
Whitepaper/Executive Summary
How Can You Ensure Successful Late-Phase Development And Launch Of Your Biologic Drug Product?
Biologics, which are expected to account for over half of all innovative drug sales by 2027, offer...
KC Video thumbnail
Video
Erik Lemay, Servier Video Testimonial
In this video, Erik Lemay, Head of Global External manufacturing at Servier discusses the...